Tissue Regenix Group plc
("Tissue Regenix" or "the Group")
2023 LTIP Grant
Tissue Regenix (AIM: TRX), the regenerative medical devices company, announces that Daniel Lee, Chief Executive Officer, and David Cocke, Chief Financial Officer, were each granted an award of restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company ("Ordinary Shares") on 21 March 2023, under the Company's existing Long-Term Incentive Plan, following the publication of its 2022 results.
Daniel Lee was awarded 19,807,390 RSUs (subsequently reduced to 198,073 RSUs following the Company's share consolidation that became effective on 28 April 2023) and David Cocke has been awarded 15,367,803 RSUs (subsequently reduced to 153,678 RSUs), where each RSU that vests shall represent the right to receive payment of one Ordinary Share. The exercise price of the RSUs was 0.1p per Ordinary Share (subsequently adjusted to 10p). The RSUs are subject to continued service over a period of three years and satisfaction of customary performance conditions relating to growth in total shareholder return, annual revenue targets, annual profitability targets and personal performance targets, further details of which will be set out in the Company's 2023 Annual Report.
Following the grant of these options, Daniel Lee and David Cocke hold options over a total of 756,897 and 514,002 RSUs respectively representing 1.1% and 0.7% of the current issued share capital respectively.
For more information:
| Tissue Regenix Group plc | |
| David Cocke, Chief Financial Officer | via Walbrook PR |
| | |
| Cavendish Capital Markets Limited (Nominated Adviser and Broker) | |
| Emily Watts/Geoff Nash/George Dollemore - Corporate Finance | |
| Nigel Birks/Harriet Ward - ECM | |
|
| |
| Walbrook PR (Financial PR and IR) | Tel: +44 (0)20 7933 8780 |
| Charlotte Edgar / Alice Woodings | TissueRegenix@walbrookpr.com |
| | |
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL®') technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient's body and can then be used to repair diseased or worn-out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care.
In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and soft tissue scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight's human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical procedures.
Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated ("PCA") with them.
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |
| a)
| Name | Daniel Lee |
| 2
| Reason for the notification | |
| a)
| Position/status
| CEO |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a)
| Name
| Tissue Regenix Group plc |
| b)
| LEI | 213800PNOD5UHQUFJI36 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a)
| Description of the financial instrument, type of instrument
| Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p |
| b) | Identification code
| GB00B5SGVL29 |
| c)
| Nature of the transaction
| Issue of options |
| d)
| Price(s) and volume(s) | Volume(s): 19,807,390 RSUs Price: 0.1 pence per RSU |
| d)
| Aggregated information - Aggregated volume - Price |
19,807,390 £19,807.39 |
| e)
| Date of the transactions | 21 March 2023 |
| f)
| Place of the transaction | Outside of a trading venue |
| 1
| Details of the person discharging managerial responsibilities / person closely associated | |
| a)
| Name | David Cocke |
| 2
| Reason for the notification | |
| a)
| Position/status
| CFO |
| b)
| Initial notification /Amendment
| Initial notification |
| 3
| Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a)
| Name
| Tissue Regenix Group plc |
| b)
| LEI | 213800PNOD5UHQUFJI36 |
| 4
| Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
| a)
| Description of the financial instrument, type of instrument
| Restricted share units ("RSUs") with respect to ordinary shares in the capital of the Company of 0.1p |
| b) | Identification code
| GB00B5SGVL29 |
| c)
| Nature of the transaction
| Issue of options |
| d)
| Price(s) and volume(s) | Volume(s): 15,367,803 RSUs Price: 0.1 pence per RSU |
| d)
| Aggregated information - Aggregated volume - Price |
15,367,803 £15,367.80 |
| e)
| Date of the transactions | 21 March 2023
|
| f)
| Place of the transaction | Outside of a trading venue |
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.